A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

NCT01815294 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Neoplasms, Ovarian
Neoplasms, Breast
Advanced or Refractory Solid Malignancies

Interventions

DRUG: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB
DRUG: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA

Sponsor

Janssen Research & Development, LLC